Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 100NIH 15NETWORK 14INDUSTRY 2FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Rare Diseases 1Oligodendroglioma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Brain Neoplasms 1Astrocytoma 1

Interventions

sargramostim 3Methods 3Granulocyte-Macrophage Colony-Stimulating Factor 3Exercise 3Colonoscopy 3Prednisone 2Palliative Care 2Leuprolide 2Golytely 2Gelatin 2Decision Support Techniques 2Collagenases 2Clofarabine 2Cholecalciferol 2Calcitriol 2ADI PEG20 2talabostat 1sulforaphane 1apalutamide 1abiraterone 1Yoga 1Water 1Tretinoin 1Topotecan 1Thioctic Acid 1Tablets 1Surgical Instruments 1Streptozocin 1Standard of Care 1Social Work 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × FED × Carmustine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡